| Mohsin Y. Meghji |
Mohsin Y. Meghji founded Loughlin, Meghji & Co. in 2002, where he worked as Managing Director & Principal from 2002 to 2011 and M III Acquisition Corp. in 2015, where he worked as Chairman & Chief Executive Officer from 2015 to 2018. Mr. Meghji also currently works at M3-Brigade Acquisition II Corp., as Chairman & Chief Executive Officer from 2020, M3-Brigade Acquisition IV Corp., as Executive Chairman from 2021, Nassau County Interim Finance Authority (New York), as Director from 2021, and various other companies. Mr. Meghji also formerly worked at Yosemite Insurance Co., as Chief Executive Officer, Merit Life Insurance Co., as Chief Executive Officer, Infrastructure & Energy Alternatives, Inc., as Chairman & Chief Executive Officer, and various other companies. Mr. Meghji received his undergraduate degree in 1987 from The Schulich School of Business. |
| Henry H. Ji |
Henry H. Ji founded Sorrento Therapeutics, Inc. in 2006, where he worked as Director & Chief Scientific Officer, Sorrento Therapeutics, Inc. in 1989, where he is working as Chairman, President & Chief Executive Officer from 2017, BioVintage, Inc. in 2002, where he is working as President from 2002, and Stratagene Genomics, Inc. in 1997, where he worked as President, Chief Executive Officer & Director from 1997 to 1999. Dr. Ji also currently works at Scintilla Pharmaceuticals, Inc., as Chief Executive Officer & Chief Financial Officer, Scilex Holding Co., as Executive Chairman from 2022, SCILEX Pharmaceuticals, Inc., as Director from 2019, and Elsie Biotechnologies Inc., as Director. Dr. Ji also formerly worked at Scilex, Inc., as Executive Chairman from 2019 to 2022, NantKwest, Inc., as Director from 2014 to 2015, Stratagene Corp., as Director-Business Development from 1999 to 2001, Hongye SD Group LLC, as Managing Director, Celularity, Inc. (United States), as Director from 2017 to 2021, CombiMatrix Corp., as Vice President from 2001 to 2002, and Quikbyte Software, Inc., as Secretary & Chief Scientific Officer in 2009. Dr. Ji received his doctorate degree from the University of Minnesota and undergraduate degree from Fudan University. |
| Shawn Sahebi |
Shawn Sahebi is currently the Senior Vice President-Commercial Operations at Sorrento Therapeutics, Inc. He previously worked as the President at the Pharmaceutical Management Science Association of America. |
| Mike A. Royal |
Dr. Mike A. Royal, MD MBA, is an Advisor at CIG Venture Management LLC. Dr. Royal has served as Vice President, Clinical Development-Analgesics, Cadence Pharmaceuticals since April 2006. From December 2004 to March 2006, he served as Chief Medical Officer of Solstice Neurosciences, a specialty biopharmaceutical company. From May 2003 to December 2004, he served as Vice President, Strategic Brand Development and Global Medical Affairs of Alpharma Inc., a global specialty pharmaceutical company. From January 2002 to May 2003, he served as Senior Medical Director of Elan Pharmaceuticals, Inc., a neuroscience-based biotechnology company. From 1994 to January 2002, he owned and managed the largest private practice pain management clinic and research center in Oklahoma.
Dr. Royal has also served as Director of the Acute Pain Service, Staff Anesthesiologist, and Assistant Professor of Anesthesiology and Critical Care Medicine at the University of Pittsburgh Medical Center. He is board certified in internal medicine, anesthesiology, pain management, and addiction medicine and has published extensively in the area of pain management.
Dr. Royal holds a B.S. in chemistry from the Massachusetts Institute of Technology, an M.D. from the University of Massachusetts, a J.D. from the University of Maryland and an M.B.A. from New York University (TRIUM). |
| Elizabeth Adkins Czerepak |
Founder of BIOptima Advisors LLC, Elizabeth Adkins Czerepak holds the position of Chief Financial Officer & Executive Vice President for Sorrento Therapeutics, Inc., Chief Financial Officer of BeyondSpring, Inc. and Chief Financial Officer, Secretary & EVP at Scilex Holding Co., Chief Financial Officer & Executive Vice President of Scilex, Inc. (a subsidiary of Scilex Holding Co.). Ms. Czerepak is also on the board of Delcath Systems, Inc. and Member of Licensing Executives Society.
In her past career Ms. Czerepak held the position of CFO, Secretary & EVP-Corporate Development at Altimmune, Inc. and Chief Financial Officer for Altimmune, Inc. (a subsidiary of Altimmune, Inc.), Chief Financial & Business Officer at Isarna Therapeutics, Inc., Managing Director at JPMorgan Chase & Co. Managing Director at Bear, Stearns & Co., Inc. and Managing Partner at Bear Stearns Health Innoventures Management LLC (both are subsidiaries of JPMorgan Chase & Co.), CFO, Secretary & Principal Accounting Officer at Cancer Genetics, Inc., Chief Financial & Business Officer at Genevant Sciences Corp., Principal at Hoffmann-La Roche, Inc., Director & Vice President-Business Development at BASF Pharma Ltd. and Director & Vice President-Business Development at Knoll Pharmaceutical Co.
Elizabeth Adkins Czerepak received an MBA from Rutgers State University of New Jersey and an undergraduate degree from Marshall University. |
| Kim D. Janda |
Kim D. Janda is the founder of CombiChem, Inc., Drug Abuse Sciences. He is currently the Director at Sorrento Therapeutics, Inc., Worm Institute For Research & Medicine, Cessation Therapeutics, LLC, and Professor at The Scripps Research Institute. He holds a doctorate degree from the University of Arizona and an undergraduate degree from the University of South Florida. |
| David Lemus |
David Lemus is the founder of Lemax LLC. He currently holds the position of Independent Non-Executive Director at Silence Therapeutics Plc, Director at Pharmaceutical Manufacturers Association of America, Independent Non-Executive Director at Sorrento Therapeutics, Inc., Treasurer & Non-Executive Director at Biohealth Innovation, Inc., Independent Director at Scilex Holding Co., Chief Financial Officer at Ironshore Pharmaceuticals (America), Inc., and Trustee at Mit Club of Washington Dc. Previously, he served as the Chief Executive Officer at Leadiant Biosciences, Inc., Chief Executive Officer at Ironshore Pharmaceuticals, Inc., Director at Axela, Inc., Independent Director at Scilex, Inc., Treasury Consultant at Electrolux AB, Group Treasurer at Chocoladefabriken Lindt & Sprüngli AG, Chief Operating & Financial Officer at MediGene AG, Chief Financial Officer & Executive Vice President at MorphoSys AG, and Chief Executive & Financial Officer at Medigene, Inc. He also held the position of Chief Operating & Financial Officer at Proteros biostructures GmbH and Manager-Pharma International Division Operations at Hoffman-La Roche, Inc. Mr. Lemus obtained a graduate degree from Massachusetts Institute of Technology, an undergraduate degree from the University of Maryland, and a graduate degree from MIT Sloan School of Management. |
| Dorman Followwill |
Dorman Followwill is currently the Lead Independent Director at Sorrento Therapeutics, Inc. and the Independent Director at Scilex Holding Co. He also holds the position of Senior Partner-Transformational Health at Frost & Sullivan, Inc. Mr. Followwill previously served as an Independent Director at Scilex, Inc. He completed his undergraduate degree at Stanford University in 1985. |
| Yue Wu |
Yue Wu was the founder of Crown Bioscience, Inc. (founded in 2006) where they held the title of President, CEO & Chief Scientific Officer until 2017. They also founded Unimicro Technologies, Inc. (founded in 2009) and Crown Bioscience International (founded in 2006) where they held the titles of Chief Operating Officer and President, Chief Executive & Strategy Officer respectively until 2017. Currently, Dr. Wu holds the position of President & Chief Executive Officer at Cothera Bioscience, Inc. (since 2018). They also hold the following current positions: Director at SCILEX Pharmaceuticals, Inc. (since 2019), Independent Director at Sorrento Therapeutics, Inc. (since 2016), Independent Director at Scilex Holding Co. (since 2023), and Independent Director at CASI Pharmaceuticals, Inc. (since 2013). Dr. Wu's former positions include Independent Director at CASI Pharmaceuticals, Inc., Manager-Business Development & Strategic Planning at F. Hoffmann-La Roche Ltd., Chief Operating Officer at Burrill LLC, and Chief Business Officer at Starvax, Inc. They also held the position of Chief Business Officer at Starvax International, Inc. (China) from 2004 to 2006. Dr. Wu's education includes an MBA and a doctorate from the University of California, Berkeley, an undergraduate degree from Fudan University, and a graduate degree from the University of Illinois At Urbana–Champaign. |
